🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “Eikon” Clear

  1. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  2. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  3. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  4. Association atezolizumab + BDB001 + RT

    Eikon Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  5. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  6. EIK1001

    Eikon Therapeutics

    NSCLC

    phase 2 small molecule active

    1 trial

  7. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  8. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  9. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  10. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  12. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  13. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. BDB001 (EIK1001)

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    2 trials

  15. BDB018

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources